TICKERNOMICS Sign up
Last Update: 2024-12-27 15:29:09
Affimed N.V. ( AFMD ) https://www.affimed.com
1.27USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
Germany
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-76.43%
AFMD
SPY
32.66%
-97.73%
AFMD
SPY
108.59%
-95.35%
AFMD
SPY
302.52%
-97.99%
AFMD
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
19.17
3.53
0.23
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.28
29.23
1.11
-133.93
0.00
-0.06
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-9214.84
100.00
-9123.59
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
12.6368
-54.11
-48.97
2.26
Other Earnings and Cash Flow Stats:
Affimed N.V. ( AFMD ) Net Income TTM ($MM) is -69.21
Affimed N.V. ( AFMD ) Operating Income TTM ($MM) is -69.01
Affimed N.V. ( AFMD ) Owners' Earnings Annual ($MM) is -118.04
Affimed N.V. ( AFMD ) Current Price to Owners' Earnings ratio is -0.57
Affimed N.V. ( AFMD ) EBITDA TTM ($MM) is -65.31
Affimed N.V. ( AFMD ) EBITDA Margin is -9123.59%
Capital Allocation:
Affimed N.V. ( AFMD ) has paid 0.00 dividends per share and bought back -1.171367 million shares in the past 12 months
Affimed N.V. ( AFMD ) has reduced its debt by 13.649704272459 million USD in the last 12 months
Capital Structure:
Affimed N.V. ( AFMD ) Interest-bearing Debt ($MM) as of last quarter is 9
Affimed N.V. ( AFMD ) Annual Working Capital Investments ($MM) are -3
Affimed N.V. ( AFMD ) Book Value ($MM) as of last quarter is 17
Affimed N.V. ( AFMD ) Debt/Capital as of last quarter is 30%
Other Balance Sheet Stats:
Affimed N.V. ( AFMD ) has 7 million in cash on hand as of last quarter
Affimed N.V. ( AFMD ) has 16 million of liabilities due within 12 months, and long term debt 10 as of last quarter
Affimed N.V. ( AFMD ) has 16 common shares outstanding as of last quarter
Affimed N.V. ( AFMD ) has 0 million USD of preferred stock value
Academic Scores:
Affimed N.V. ( AFMD ) Altman Z-Score is -24.71 as of last quarter
Affimed N.V. ( AFMD ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
Affimed N.V. ( AFMD ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of Affimed N.V. ( AFMD ) for the amount of $ on
6.01% of Affimed N.V. ( AFMD ) is held by insiders, and 36.98% is held by institutions
Affimed N.V. ( AFMD ) went public on 2014-09-12
Other Affimed N.V. ( AFMD ) financial metrics:
FCF:-72.47
Unlevered Free Cash Flow:-133.74
EPS:-3.76
Operating Margin:-9214.84
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-352.17
Beta:2.26
Buffet's Owners Earnings:-118.04
Price to Owner's Earnings:-0.57
About Affimed N.V. ( AFMD ) :
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia. The company also develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. In addition, it has collaboration with Artiva Biotherapeutics to develop the combination of AFM13 with Artiva's AB-101 NK cell therapy; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and research collaboration and license agreement with Genentech for the development and commercialization of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.